180
Z. Liu et al.
journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT
and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT
Achievement award in 2002, the EUROTOX Bo Holmstedt award in 2009 and the SOT Founders
award in 2018 for outstanding leadership in toxicology.
Weida Tong is Director of Division of Bioinformatics and Biostatistics at FDA’s National Center for Toxicological Research (NCTR/FDA). He has served as a science advisory board member for several large projects involving multiple institutes in Europe and the USA. He also holds
several adjunct positions at universities in the USA and China. His division at FDA works to
develop bioinformatic methodologies and standards to support FDA research and regulation and to
advance regulatory science and personalized medicine. The most visible projects from his group
are (1) leading the Microarray Quality Control (MAQC) consortium to develop standard analysis
protocols and quality control metrics for emerging technologies to support regulatory science and
precision medicine; (2) development of liver toxicity knowledge base (LTKB) for drug safety; (3)
in silico drug repositioning for the enhanced treatment of rare diseases; and (4) development of the
FDA bioinformatics system, ArrayTrackTM suite, to support FDA review and research on pharmacogenomics. In addition, his group also specializes in molecular modeling and QSARs with
specific interest in estrogen, androgen, and endocrine disruptor. Dr. Tong has published more than
230 papers and book chapters.
Z. Liu et al.
journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT
and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT
Achievement award in 2002, the EUROTOX Bo Holmstedt award in 2009 and the SOT Founders
award in 2018 for outstanding leadership in toxicology.
Weida Tong is Director of Division of Bioinformatics and Biostatistics at FDA’s National Center for Toxicological Research (NCTR/FDA). He has served as a science advisory board member for several large projects involving multiple institutes in Europe and the USA. He also holds
several adjunct positions at universities in the USA and China. His division at FDA works to
develop bioinformatic methodologies and standards to support FDA research and regulation and to
advance regulatory science and personalized medicine. The most visible projects from his group
are (1) leading the Microarray Quality Control (MAQC) consortium to develop standard analysis
protocols and quality control metrics for emerging technologies to support regulatory science and
precision medicine; (2) development of liver toxicity knowledge base (LTKB) for drug safety; (3)
in silico drug repositioning for the enhanced treatment of rare diseases; and (4) development of the
FDA bioinformatics system, ArrayTrackTM suite, to support FDA review and research on pharmacogenomics. In addition, his group also specializes in molecular modeling and QSARs with
specific interest in estrogen, androgen, and endocrine disruptor. Dr. Tong has published more than
230 papers and book chapters.